David Lewis

TL;DR: Reduction of LDL cholesterol with simvastatin 20 mg plus ezetimibe 10 mg daily safely reduced the incidence of major atherosclerotic events in a wide range of patients with advanced chronic kidney disease.

TL;DR: Lowering LDL cholesterol by 1 mmol/L did not slow kidney disease progression within 5 years in a wide range of patients with CKD and showed no significant effect on the rate of change in eGFR.

TL;DR: In this paper, the relevance of the cause of kidney disease to prognosis among patients with chronic kidney disease is uncertain, however, the authors found that patients with cystic kidney disease are at much higher risk of end-stage renal disease (ESRD) and much lower risk of death before ESRD.

TL;DR: Patients with cystic kidney disease are at much higher risk of end-stage renal disease (and much lower risk of death before ESRD) than other patients, and patients with diabetic nephropathy are at particularly high risk of life-threatening death prior to reaching E SRD.

TL;DR: The hypothesis that minimizing CNI exposure with Campath-based induction therapy and/or an elective conversion to sirolimus-based maintenance therapy can improve long-term graft function and survival is correct, then patients should experience better graft function for longer.